INSEAD Day 4 - 728x90

TECOM profit climbs

High occupancy across assets boosts earnings.

Emirates Stallions Q1 revenue up 11%

The rise helped by strong demand in real estate

ADNOC Distribution 2025 dividend $700m

The company had reported EBITDA of $1.17 bn in 2025.

Empower okays $119.1m H2 2025 dividend

The dividend is equivalent to 43.75% of paid-up capital.

Alujain widens 2025 loss

The increase in loss is due to impairment charges, weaker prices.

SFDA, SBA partner to create media content on health, food

The Saudi Food and Drug Authority and the Saudi Broadcasting Authority partner to create media content on health and food.
  • The agreement aims to create joint media sponsorship opportunities that serve both sides and to establish specialized media publications
  • The areas of cooperation include educating consumers on the safe use of cosmetic products, making television programs and providing visual and audio content

The Saudi Food and Drug Authority (SFDA) and the Saudi Broadcasting Authority (SBA) signed on Wednesday a memorandum of cooperation (MoC) to create and publish specialized and professional media content on health and food.

The MOC was signed by SFDA’s CEO, Dr. Hisham bin Saad Aljadhey, and the CEO of SBA, Mohammad bin Fahad Al-Harthi.

The MoC aims to create joint media sponsorship opportunities that serve both sides, and to establish specialized media publications, in addition to covering, transferring and managing events, media centers and local SFDA events.

The MoC includes holding joint training programs to develop human resources in related fields, exchanging experiences, transferring knowledge, and benefiting from the facilities of both sides to create television programs and visual productions.

The areas of cooperation include educating consumers on the safe use of cosmetic products, making television programs and providing visual and audio content such as podcasts, educational clips between program times regarding nutrition and public health. 

A mechanism will also be put in place to not publish any advertisements for pharmaceutical companies, food or medical devices and products until verifying that they have obtained prior approval to advertise their products.